Antidotes to newer anticoagulants clear first hurdle

The first major studies looking at antidotes for novel oral anticoagulants (NOACs) have shown they can reverse anticoagulant effects in patients who have experienced a major bleeding episode or in those who require emergency surgery.

The results come from two Phase III studies into two antidotes with differing modes of action that were presented at a thrombosis conference in Toronto, Canada, on Monday.

The trials demonstrate that idarucizumab